Funding Round Overview

Recursion announced a funding round on August 1, 2023 totaling $100,000,000. AI drug discovery company Recursion acquired Cyclica and Valence for $100M combined. $100M in acquisitions.

Deal Highlights

• Capital involved: $100,000,000.
• Acquirer: Recursion.

Company and Sector Context

Recursion builds in the healthcare ai sector, one of the most active areas in AI investment today. Based in United States, the company is part of a global wave of startups scaling AI into production across regulated and enterprise environments.

How the Capital Helps

Disclosed details include $100M in acquisitions. In healthcare ai, speed to market and access to high-quality talent often determine category leadership.

Competitive Landscape

Funding activity in healthcare ai continues to intensify as incumbents and startups race to ship reliable AI systems. This round signals ongoing investor confidence in differentiated technology and defensible distribution.

Looking Ahead

This funding positions Recursion for continued growth in the healthcare ai landscape. As AI adoption accelerates across industries, deals like this signal where capital and strategic attention are moving next.